narcolepsy
NARCOLEPSY

Narcolepsy is a chronic neurologic sleep disorder wherein the patient have excessive daytime sleepiness and rapid eye movement sleep is dysregulated.

It affects 1 in 1000 individuals, with prevalence of about 0.04% of general population.
The exact cause remains unclear.
Studies suggest a combination of genetic predisposition, abnormal neurotransmitter functioning and abnormal immune modulation.
Symptoms include excessive daytime sleepiness, cataplexy, sleep paralysis, sleep-related hallucinations, automatic behavior, fragmented nocturnal sleep and insomnia.

Narcolepsy Management

Prevention

Scheduled Naps

  • Regular scheduled short daytime naps can decrease sleepiness & improve alertness
    • Fifteen- to twenty-minute naps every 4 hours during daytime are recommended
    • Usually combined with other therapies

Other Management Approaches

  • Avoid sleep deprivation
  • Avoid frequent time zone changes
  • Practice good sleep hygiene
  • Regular exercise
    • Increases daytime energy & improves sleeping patterns

Follow Up

  • Regular follow-up every 6 months to 1 year is advised once stabilized on medication
    • Monitor compliance & response to treatment
    • Assess development of side effects (eg sleep disturbances, mood changes, cardiovascular & metabolic problems)
    • Assist patients in adapting to the disorder
Editor's Recommendations
Most Read Articles
Pearl Toh, 24 Jun 2020
While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.
Elvira Manzano, 24 Oct 2018
New evidence showed that a high-fat, low-carbohydrate ketogenic diet could help improve symptoms in patients with Parkinson's disease (PD), so did a low-fat, high-carbohydrate diet.
Natalia Reoutova, 4 days ago

Consistent with the overall outcome of the phase III EF-14 study, elderly patients with newly diagnosed glioblastoma multiforme (GBM) treated with tumour-treating fields (TTFields) and temozolomide (TMZ) showed significantly better overall survival (OS) vs patients on TMZ alone, according to a post-hoc analysis presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.